HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Insmed, maintaining a price target of $90. This suggests confidence in Insmed's future performance.
August 29, 2024 | 11:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Insmed, maintaining a price target of $90. This suggests confidence in Insmed's future performance.
The reiteration of a Buy rating and maintenance of a $90 price target by HC Wainwright & Co. indicates a positive outlook for Insmed. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100